Overcoming Immune Evasion in Melanoma.
Overcoming Immune Evasion in Melanoma.
复制标题
DOI：
10.3390/ijms21238984
复制
发表时间：
2020-11-26
影响因子：
5.6
通讯作者：
Chen S
中科院分区：
文献类型：
--
作者：
Eddy K;Chen S
Melanoma is the most aggressive and dangerous form of skin cancer that develops from transformed melanocytes. It is crucial to identify melanoma at its early stages, in situ, as it is “curable” at this stage. However, after metastasis, it is difficult to treat and the five-year survival is only 25%. In recent years, a better understanding of the etiology of melanoma and its progression has made it possible for the development of targeted therapeutics, such as vemurafenib and immunotherapies, to treat advanced melanomas. In this review, we focus on the molecular mechanisms that mediate melanoma development and progression, with a special focus on the immune evasion strategies utilized by melanomas, to evade host immune surveillances. The proposed mechanism of action and the roles of immunotherapeutic agents, ipilimumab, nivolumab, pembrolizumab, and atezolizumab, adoptive T- cell therapy plus T-VEC in the treatment of advanced melanoma are discussed. In this review, we implore that a better understanding of the steps that mediate melanoma onset and progression, immune evasion strategies exploited by these tumor cells, and the identification of biomarkers to predict treatment response are critical in the design of improved strategies to improve clinical outcomes for patients with this deadly disease.
登录
查看更多内容
PD-1和PD-L1检查点信号传导抑制癌症免疫疗法：机制，组合和临床结果。
影响因子：
5.6
作者：
Alsaab HO;Sau S;Alzhrani R;Tatiparti K;Bhise K;Kashaw SK;Iyer AK
通讯作者：
Iyer AK
影响因子：
--
作者：
Arasanz H;Gato-Cañas M;Zuazo M;Ibañez-Vea M;Breckpot K;Kochan G;Escors D
通讯作者：
Escors D
影响因子：
--
作者：
Aalborg, Jenny;Morelli, Joseph G.;Crane, Lori A.
通讯作者：
Crane, Lori A.
影响因子：
45.3
作者：
Ascierto, Paolo A.;Minor, David;Trefzer, Uwe
通讯作者：
Trefzer, Uwe
影响因子：
3.8
作者：
Bardi GT;Smith MA;Hood JL
通讯作者：
Hood JL